Ziz
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
ZIZ Extra Strength
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Promethazine Hydrochloride 25 mg, also contains lactose.
3 PHARMACEUTICAL FORM
Coated tablet
Blue sugar-coated tablet
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
As symptomatic treatment of allergic conditions of the upper respiratory tract and skin: including allergic rhinitis, urticaria and anaphylactic reactions to drugs or foreign proteins
As an antiemetic.
As an adjunct in preoperative sedation in surgery and obstetrics.
For short term use:
Sedation and treatment of insomnia in adults.
As a paediatric sedative.
4.2 Posology and method of administration
To be taken orally.
Not for use in children under the age of 2 years because the safety of such use has not been established.
As an antihistamine in allergy:
|
Children 2-5 years |
The use of Promethazine liquid is recommended for this age group. |
|
Children 5-10 years |
25 mg as a single dose*. Maximum daily dose 25 mg. |
|
Children over 10 years and adults (including elderly) |
25 mg as a single dose*. Increasing to a maximum of 25 mg twice a day as required. |
*Single doses are best taken at night.
As an antiemetic:
|
Children 2-5 years |
The use of Promethazine liquid is recommended for this age group. |
|
Children 5-10 years |
The use of Promethazine liquid or Promethazine 10mg tablet indicated as an antiemetic is suitable. |
|
Children over 10 years and adults (including elderly) |
25 mg to be taken the night before the journey. To be repeated after 6-8 hours as required. |
Short-term sedation:
|
Children 2-5 years |
The use of Promethazine liquid is recommended for this age group. |
|
Children 5-10 years |
25 mg given as a single night-time dose. |
|
Children over 10 years and adults (including elderly) |
One 25 mg tablet at night, may be increased to two 25 mg tablets at night if necessary. |
4.3 Contraindications
Ziz Extra Strength should not be used in patients:
• in coma or
• suffering from CNS depression of any cause or,
• with a known hypersensitivity to promethazine or other phenothiazines, or any of the inactive ingredients of the tablet.
Ziz Extra Strength is contraindicated for use in children less than two years old because of the potential for fatal respiratory depression. (This includes neonates and premature infants.)
Ziz Extra Strength should be avoided in patients taking monoamine oxidase inhibitors up to 14 days previously.
4.4 Special warnings and precautions for use
Promethazine hydrochloride should be used with caution in patients with hepatic disease.
Promethazine may thicken or dry lung secretions and impair expectoration. Therefore caution should be exercised in patients who might be at risk from the anti-cholinergic actions of the drug, including those with asthma, bronchitis or bronchiectasis.
Use with caution in patients with severe coronary disease, narrow angle glaucoma, epilepsy, urinary retention, renal insufficiency (where dose reduction may be necessary).
Caution should be exercised in patients with prostatic hypertrophy and bladder neck or pyloro-duodenal obstruction.
Promethazine may mask the warning signs of ototoxicity caused by ototoxic drugs e.g. salicylates. It may also delay the early diagnosis of intestinal obstruction or raised intracranial pressure through the suppression of vomiting.
Promethazine should be prescribed with caution in children and the elderly, as they are more susceptible to side effects.
The use of promethazine should be avoided in children and adolescents with signs and symptoms suggestive of Reye’s syndrome.
Patients with rare hereditary problems of lactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Promethazine should not be used for more than 7 days without seeking medical advice.
4.5 Interaction with other medicinal products and other forms of interaction
Promethazine will enhance the action of any anti-cholinergic agent, tricyclic antidepressant, sedative, hypnotic or other Central Nervous System depressant drug given concurrently. Alcohol should be avoided during treatment.
Promethazine should be avoided in patients taking monoamine oxidase inhibitors due to increased anti-muscarinic and sedative effects.
Promethazine may interfere with immunological urine pregnancy tests and cause false- positive or false-negative results.
Promethazine should be discontinued at least 72 hours before the start of skin tests as it may inhibit the cutaneous histamine response and thus produce false-negative results.
4.6 Pregnancy and lactation
Promethazine should not be used in pregnancy unless the physician considers it essential. The use of Promethazine is not recommended in the 2 weeks prior to delivery in view of the risk of irritability and excitement in the neonate.
Available evidence suggests that the amount of Promethazine excreted in breast milk is insignificant. However, there are risks of neonate irritability and excitement.
4.7 Effects on ability to drive and use machines
Because the duration of action may be up to 12 hours, patients should be advised that if they feel drowsy they should not drive or operate heavy machinery.
Ambulant patients receiving Promethazine should not be in control of vehicles or machinery for the first few days until it is established that they are not hypersensitive to the Central Nervous System effects of the drug, and do not suffer from confusion, disorientation or dizziness.
4.8 Undesirable effects
Side effects include drowsiness, dizziness, restlessness, headache, psychomotor impairment, nightmares, tiredness, and disorientation.
Anticholinergic side effects such as urinary retention, dry mouth, blurred vision, difficulty in lachrymation and gastrointestinal disturbances, like constipation occur occasionally. Retention of urine may exacerbate the symptoms of prostatism.
Infants are susceptible to the anticholinergic effects of promethazine, while other children may display paradoxical hyperexcitability.
The elderly are more prone to the anti-cholinergic effects and confusion due to promethazine.
Other side effects include urticaria, rashes, pruritus, anorexia, gastric irritation, palpitations, arrhythmias, hypotension, extrapyramidal effects, confusion, depression, sleep disturbances, tremor, convulsions, muscle spasms and tic-like movements of the head and face.
Anaphylaxis, jaundice, blood dyscrasias including haemolytic anaemia or liver dysfunction rarely occur.
Hypersensitivity reactions include bronchospasm, angioedema, skin reactions and photosensitivity reactions have been reported; strong sunlight should be avoided during treatment.
4.9 Overdose
The symptoms of severe overdose are variable. They are characterised in children by various combinations of excitation, ataxia, unco-ordination, athetosis and hallucinations, while adults may become drowsy and lapse into coma. Convulsions may occur in both adults and children; coma or excitement may precede their occurrence. Cardiorespiratory depression is uncommon.
If the patient is seen soon enough after ingestion, it should be possible to induce vomiting with ipecacuanha despite the anti-emetic effect of Promethazine; alternatively, gastric lavage may be used.
Treatment is otherwise supportive with attention to maintenance of adequate respiratory and circulatory status. Convulsions should be treated with Diazepam or other suitable anticonvulsant.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Promethazine Hydrochloride is a phenothiazine derivative with properties of
prolonged antihistamine action. It also has some anticholinergic, antiserotoninergic and marked local anaesthetic properties. Promethazine Hydrochloride diminishes the main actions of histamine in the body, probably by occupying the receptor sites in the effector cells to the exclusion of histamine, but does not prevent the production of histamine.
Promethazine is a H1-receptor antagonist and thereby mediates the contraction of smooth muscle and the dilation and increased permeability of the capillaries.
5.2 Pharmacokinetic Properties
Promethazine is well absorbed after oral dosing with extensive first-pass effect. It is highly bound to plasma proteins. It is slowly excreted via urine and bile. It is distributed widely in the body. It enters the brain and crossed the placenta. Phenothiazines pass into the milk at low concentrations.
5.3 Preclinical Safety Data
No relevant information additional to that contained elsewhere in the SPC.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Core:
Lactose Maize Starch
Maize Starch, Pregelatinised Magnesium Stearate
Coating:
Bleached Shellac Talc
Titanium Dioxide Povidone
Opalux Blue AS-F-4321G (contains Indigo Carmine E132, Patent Blue E131, Titanium Dioxide E171 and Sodium Benzoate E211)
Sucrose Beeswax Carnauba Wax
6.2 Incompatibilities
Promethazine Hydrochloride is incompatible with alkaline substances which precipitate Promethazine Base.
6.3 Shelf Life
Polystyrene/polypropylene containers - 36 months PVC/Aluminium strips - 24 months
6.4 Special precautions for storage
Containers: Do not store above 25°C. Keep the container tightly closed. Store in the original container.
Strips: Do not store above 25°C. Store in the original package. Keep container in the outer carton.
6.5 Nature and contents of container
High density polystyrene with polythene lids and/or polypropylene containers with polypropylene or polythene lids and polyurethane/polythene inserts.
Packs of 100, 500 and 1000 tablets.
PVC/Aluminium foil strips.
Packs of 10, 30 and 56 tablets.
6.6 Special precautions for disposal
No special precautions.
7 MARKETING AUTHORISATION HOLDER
Chatfield Pharmaceuticals Limited T/A Chatfield Laboratories Kramer Mews London SW5 9JL United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 02142/0027
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
28/11/2006
10 DATE OF REVISION OF THE TEXT
31/12/2013